Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer

Giorgio Stassi, Matilde Todaro, Tiziana Apuzzo, Adriana Eramo, Ann Zeuner, Mauro Biffoni, Ruggero De Maria, Sette, Federica Francescangeli, Giuseppina Zapparelli, Contavalli, Baiocchi, De Angelis

Risultato della ricerca: Article

49 Citazioni (Scopus)

Abstract

Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC
Lingua originaleEnglish
pagine (da-a)1877-1888
Numero di pagine12
RivistaCell Death and Differentiation
Volume21
Stato di pubblicazionePublished - 2014

Fingerprint

Neoplastic Stem Cells
Non-Small Cell Lung Carcinoma
Lung Neoplasms
gemcitabine
Heterografts
Neoplasms
Cell Survival
Cell Death
Stem Cells
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cita questo

Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. / Stassi, Giorgio; Todaro, Matilde; Apuzzo, Tiziana; Eramo, Adriana; Zeuner, Ann; Biffoni, Mauro; De Maria, Ruggero; Sette; Francescangeli, Federica; Zapparelli, Giuseppina; Contavalli; Baiocchi; De Angelis.

In: Cell Death and Differentiation, Vol. 21, 2014, pag. 1877-1888.

Risultato della ricerca: Article

Stassi, G, Todaro, M, Apuzzo, T, Eramo, A, Zeuner, A, Biffoni, M, De Maria, R, Sette, Francescangeli, F, Zapparelli, G, Contavalli, Baiocchi & De Angelis 2014, 'Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer', Cell Death and Differentiation, vol. 21, pagg. 1877-1888.
Stassi, Giorgio ; Todaro, Matilde ; Apuzzo, Tiziana ; Eramo, Adriana ; Zeuner, Ann ; Biffoni, Mauro ; De Maria, Ruggero ; Sette ; Francescangeli, Federica ; Zapparelli, Giuseppina ; Contavalli ; Baiocchi ; De Angelis. / Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. In: Cell Death and Differentiation. 2014 ; Vol. 21. pagg. 1877-1888.
@article{1cc6509203d547a6a82a8c3219fcae28,
title = "Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer",
abstract = "Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC",
author = "Giorgio Stassi and Matilde Todaro and Tiziana Apuzzo and Adriana Eramo and Ann Zeuner and Mauro Biffoni and {De Maria}, Ruggero and Sette and Federica Francescangeli and Giuseppina Zapparelli and Contavalli and Baiocchi and {De Angelis}",
year = "2014",
language = "English",
volume = "21",
pages = "1877--1888",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer

AU - Stassi, Giorgio

AU - Todaro, Matilde

AU - Apuzzo, Tiziana

AU - Eramo, Adriana

AU - Zeuner, Ann

AU - Biffoni, Mauro

AU - De Maria, Ruggero

AU - Sette, null

AU - Francescangeli, Federica

AU - Zapparelli, Giuseppina

AU - Contavalli, null

AU - Baiocchi, null

AU - De Angelis, null

PY - 2014

Y1 - 2014

N2 - Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC

AB - Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC

UR - http://hdl.handle.net/10447/163835

M3 - Article

VL - 21

SP - 1877

EP - 1888

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

ER -